Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $148 | $147 | $141 | $142 |
| % Growth | 1.2% | 3.6% | -0.3% | – |
| Cost of Goods Sold | $25 | $30 | $18 | $22 |
| Gross Profit | $123 | $117 | $124 | $120 |
| % Margin | 82.9% | 79.6% | 87.3% | 84.7% |
| R&D Expenses | $3 | $4 | $4 | $4 |
| G&A Expenses | $45 | $42 | $44 | $14 |
| SG&A Expenses | $47 | $46 | $47 | $44 |
| Sales & Mktg Exp. | $3 | $4 | $3 | $31 |
| Other Operating Expenses | $7 | $0 | $9 | $9 |
| Operating Expenses | $57 | $50 | $60 | $57 |
| Operating Income | $66 | $66 | $63 | $63 |
| % Margin | 44.7% | 45.2% | 44.8% | 44.3% |
| Other Income/Exp. Net | $5 | $3 | $8 | $11 |
| Pre-Tax Income | $71 | $69 | $71 | $74 |
| Tax Expense | $18 | $17 | $15 | $18 |
| Net Income | $53 | $52 | $57 | $56 |
| % Margin | 35.6% | 35.6% | 40.1% | 39.4% |
| EPS | 0.43 | 0.43 | 0.47 | 0.47 |
| % Growth | 0% | -8.5% | 0% | – |
| EPS Diluted | 0.42 | 0.41 | 0.45 | 0.44 |
| Weighted Avg Shares Out | 123 | 122 | 121 | 120 |
| Weighted Avg Shares Out Dil | 127 | 128 | 127 | 126 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $6 | $5 | $5 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $9 | $9 | $9 | $9 |
| EBITDA | $80 | $79 | $73 | $72 |
| % Margin | 54.2% | 53.7% | 51.5% | 51% |